Effect of low-dose rapamycin on the therapeutic response to radio-immunotherapy in hepatocellular carcinoma. Multi-omics analysis of PD-1 inhibitor combination in neoadjuvant treatment of pMMR/MSS ...
The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...
Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...
PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
NEW ROCHELLE, N.Y., March 5, 2025 /PRNewswire/ -- A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models (LLMs) to rapidly extract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results